Prothena Corp Public (PRTA) Operating Leases (2019 - 2026)
Prothena Corp Public (PRTA) posted quarterly Operating Leases of $4.8 million for Q1 2026, down 53.34% year-over-year from $10.2 million in Q1 2025, and down 13.23% quarter-over-quarter from $5.5 million in Q4 2025.
Prothena Corp Public (PRTA) Operating Leases (2019 - 2026) Analysis & Trends
Prothena Corp Public's Operating Leases history runs 8 years deep, the most recent figure standing at $4.8 million for Q1 2026.
- In Q1 2026, Operating Leases fell 53.34% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (down 53.34% YoY), while the FY2025 annual figure was $5.5 million, down 33.35% from the prior year.
- Operating Leases for Q1 2026 stood at $4.8 million, down from $5.5 million in the prior quarter.
- The five-year high for Operating Leases was $12.5 million in Q1 2024, with the low at $3.4 million in Q2 2023.
- The 5-year median for Operating Leases is $9.3 million (2024), against an average of $8.6 million.
- The sharpest annual moves came in 2023 and 2024: Operating Leases slumped 64.0% in 2023, then surged 176.62% in 2024.
- Prothena Corp Public's Operating Leases stood at $8.0 million in 2022, then jumped by 33.45% to $10.7 million in 2023, then decreased by 23.21% to $8.2 million in 2024, then tumbled by 33.35% to $5.5 million in 2025, then decreased by 13.23% to $4.8 million in 2026.
- Business Quant data shows PRTA's Operating Leases at $4.8 million in Q1 2026, $5.5 million in Q4 2025, and $9.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.99 Mn |
| Mar 31, 2026 | 4.76 Mn |
| Dec 31, 2025 | 5.49 Mn |
| Sep 30, 2025 | 9.08 Mn |
| Jun 30, 2025 | 9.78 Mn |
| Mar 31, 2025 | 10.20 Mn |
| Dec 31, 2024 | 8.23 Mn |
| Sep 30, 2024 | 11.49 Mn |
| Jun 30, 2024 | 9.54 Mn |
| Mar 31, 2024 | 12.50 Mn |
| Dec 31, 2023 | 10.72 Mn |
| Sep 30, 2023 | 8.92 Mn |
| Jun 30, 2023 | 3.45 Mn |
| Mar 31, 2023 | 4.89 Mn |
| Sep 30, 2022 | 8.03 Mn |
| Jun 30, 2022 | 9.58 Mn |
| Mar 31, 2022 | 10.88 Mn |
| Dec 31, 2021 | 6.39 Mn |
| Sep 30, 2021 | 13.75 Mn |
| Jun 30, 2021 | 9.43 Mn |